CDP791
Facts from the Community
From the BioVenturist base
Indication or disease:
| Disease | Phase of development |
|---|---|
Developed by:
Stage of development:
We can tell you that CDP791 is a…
If you know more about CDP791, you can add more facts here »
Similar topics in Freebase
-
Fesoterodine
Fesoterodine (INN, brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome. It was approved by the European Medicines Agency in April 2007 and was approved by the US Food and Drug Administration on October 31, 2008. Fesoterodine is a prodrug.... -
CMC544
-
Lacosamide
Lacosamide (INN, formerly known as erlosamide) is a medication developed by UCB for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain marketed under the trade name Vimpat. The U.S. Food and Drug Administration accepted UCB's New Drug Application for lacosamide as of... -
Certolizumab pegol
Certolizumab pegol (CDP870, tradename Cimzia) is a therapeutic monoclonal antibody for the treatment of Crohn's disease produced by UCB . It is also investigated for use against rheumatoid arthritis. Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More... -
Rikelta
-
Rotigotine transdermal system
-
Rotigotine nasal spray
-
Epratuzumab
Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE). -
Anti-Sclerostin
-
Xyrem
This article describes the status of Xyrem as a prescription drug. To learn about the chemical and its biological mode of action, see the article on gamma-hydroxybutyric acid. Xyrem is a trade name for gamma-hydroxybutyric acid or GHB, an endogenous neurochemical involved in regulating metabolism,...
